SYSTEMATIC REVIEW

Effect of Drugs on Orthodontic Tooth Movement in Human Beings: A Systematic Review of Randomized Clinical Trials

Khaled Khalaf* and Mahmoud Mando

Department of Orthodontics, College of Dental Medicine (Building M28), University of Sharjah, PO Box 27272, Sharjah, United Arab Emirates

Abstract:
Background: Orthodontic tooth movement represents a series of events at both cellular and molecular levels which in turn stimulates inflammatory pathway to induce tooth movement. Some drugs taken by patients have a negative effect which can block this pathway, on the other hand, others may influence these events and reduce treatment time.

Search Methods: A search strategy was implemented using both manual hand search and electronic databases, including Cochrane database of clinical trials, PubMed, ScienceDirect and Scopus. The risk of biased eligible studies to be included in the final analysis was assessed independently by two authors using Cochrane risk of bias tool.

Results: A total of 491 articles were identified in both manual and electronic searches as well as by checking the reference lists of articles to be included in the study. After reviewing the titles, abstracts and full-text articles, only 8 RCTs met the inclusion criteria, and thus, were included in the final analysis. Six out of the 8 RCTs were assessed as of low quality. No statistical methods were employed to combine the studies due to the heterogeneities of the studies and the low level of evidence.

Conclusion: Acetylsalicylic acid and ibuprofen reduced orthodontic tooth movement whereas paracetamol, Rofecoxib and tenoxicam had no impact on orthodontic tooth movement. Due to the low quality of the studies included, therefore to base our practice on scientific evidence, better-controlled RCTs are needed to investigate the impact of common medications on orthodontic tooth movement.

Keywords: Orthodontic tooth movement, Drugs, Medications, Pharmaceutics, Analgesics, Acceleration, Inhibition, Drugs effect.

Article History
Received: August 14, 2018 Revised: November 20, 2018 Accepted: December 9, 2018

1. INTRODUCTION

1.1. Rationale

One of the most common disadvantages of orthodontic treatment is being lengthy and thus expensive. When teeth are subjected to orthodontic force, a series of biological events take place to induce tooth movement. First, the applied mechanical force causes interstitial fluid to be expressed through canaliculi and apply pressure on the surrounding ECM and cells. Mechanoreceptors represented by osteocytes in the lining of alveolar socket and fibroblast in the PDL can detect the strain. This strain on bone ECM and cells result in the stimulation of transmembrane protein called Integrins which attach the cell cytoskeleton to its extracellular matrix [1, 2]. Integrin stimulation activates the signal transducing pathway triggering osteocyte differentiation into osteoblast and osteoclast to build and resorb bone. As a result, intracellular calcium increases, promoting the activation of phospholipase A2 which is responsible for the hydrolysis of glycerophospholipids to yield arachidonic acid. Then arachidonic acid is converted by Cyclooxygenase (COX) enzymes to produce prostaglandins which play the key role in the inflammatory process [1 - 3]. Orthodontists often prescribe drugs to manage pain and discomfort resulting from orthodontic treatment, mostly...
acetylsalicylic acid, ibuprofen, and paracetamol [4 - 6], which in turn block prostaglandin synthesis and may result in slower tooth movement. On the other hand, many methods including biological methods [7 - 9], device-assisted treatment [10 - 14] and surgical approach [15 - 18] have been investigated recently to reduce orthodontic treatment time by accelerating tooth movement. Therefore, the aim of this study was to investigate the effect of various drugs on orthodontic tooth movement.

1.2. Objectives

By summarizing evidence from existing randomized clinical trials, the aim of this systematic review was to investigate the effect of commonly used drugs on orthodontic tooth movement and whether some of them may play a role as a minimally invasive procedure to accelerate orthodontic tooth movement and reduce treatment time.

2. MATERIALS AND METHODS

2.1. Protocol and Registration

The present systematic review was conducted using the Prisma checklist guidelines and registered in Prospero (International Prospective Register of Systematic Reviews) under the registration number CRD42019 115908.

2.2. Information Sources and Search Strategy

A comprehensive search strategy was implemented using both manual and electronic search methods in order to identify both indexed and non-indexed articles in databases as well as to reduce the possibility of excluding relevant studies by chance. The online database search strategy incorporated the following databases: Cochrane database of clinical trials, PubMed, ScienceDirect and Scopus until April 2018 using the following keywords:

- (tooth or teeth or orthodontic*) and move* and (drug* or medic*);
- (tooth or orthodontic) and movement and (drug or medication);
- (drug or medication) and (tooth or orthodontic*) and movement;
- (drug* OR medication OR pharmaceutical OR analgesics OR non-steroidal anti-inflammatory drugs OR bisphosphonate OR relaxin OR fluoride OR hormone OR vitamin) AND ("tooth movement" OR "teeth movement" OR "orthodontic* movement").

The manual hand search incorporated the following journals:

1. Journal of Orthodontics (2005-2018);
2. European Journal of Orthodontics (2009-2018);
3. American Journal of Orthodontics and Dento-facial Orthopedics (2000-2018);

2.3. Eligibility Criteria

Articles were comprehensively examined against the inclusion and exclusion criteria and only studies carried out on humans and specifically randomized clinical trials were included in the systematic review. Abstracts, titles and subsequently full texts of potential articles were examined carefully and independently by two authors to make sure they were eligible to meet the inclusion criteria. Furthermore, references of all reviewed articles were assessed carefully for their eligibility to meet the inclusion criteria.

2.4. Risk of Bias in Individual Trials

All articles included in the study were reviewed independently by two authors in order to assess the level of bias using Cochrane risk of bias tool shown in Table 1, which is an assessment tool that entails quality assessment based on five factors including selection bias (allocation concealment and methods of randomization), detection bias, performance bias, reporting bias and attrition bias [19]. Using the Grade approach (Grading of Recommendations Assessment, Development and Evaluation), the overall quality of evidence was assessed based on five factors: risk of bias, inconsistency, imprecision, indirectness and publication bias. The grade ratings of high, moderate, low, very-low quality evidence reflect how confident we are that the true effect lies close to the estimated effect in the systematic review [20].

3. RESULTS

3.1. Study Selection

The flowchart in Fig. (1) identifies the included and excluded articles at each stage. 507 articles were assessed, including 489 articles from the electronic databases, 16 from the manual hand search and 2 articles from the reference lists. 16 articles were duplicates, and 346 did not relate to the research question, thus leaving 145 articles for potential inclusion in the study. Following the inspection of the full text of these articles, 116 were excluded as they were experimental animal studies and further 21 were also excluded due to different reasons (12 reviews, 5 systematic reviews, 1 cohort and 3 case reports). This means only 8 randomized clinical trials were included in the review for further analysis. The process of searching and selection of studies to be included in the review was carried out independently and in duplicate by the 2 authors and any disagreement was resolved through a discussion between them. The kappa statistic for agreement between the reviewers was 0.86.

3.2. Risk of Bias Within Studies

Using the Cochrane risk of bias tool, the quality of evidence of all papers included was ranging between low to high-quality evidence. Only two of the included studies had a high-quality evidence as they were double-blinded randomized clinical trials with a clear method of randomization and allocation concealment. The remaining 6 papers had a low-quality evidence due to either not stating the method of randomization or blinding the participants and personnel (Fig. 2). According to the Grade system, the overall quality of evidence was observed to range between low to high (Table 2). However, due to the low evidence of the studies included and their heterogeneities, no formal data synthesis or meta-analysis was undertaken.
Table 1. The Cochrane Collaboration’s tool for assessing risk of bias.

<table>
<thead>
<tr>
<th>Domain</th>
<th>Support for Judgement</th>
<th>Review Authors’ Judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Selection bias.</td>
<td>Describe the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups.</td>
<td>Selection bias (biased allocation to interventions) due to inadequate generation of a randomized sequence.</td>
</tr>
<tr>
<td>Random sequence generation.</td>
<td>Describe the method used to conceal the allocation sequence in sufficient detail to determine whether intervention allocations could have been foreseen in advance of, or during, enrolment.</td>
<td>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment.</td>
</tr>
<tr>
<td>Allocation concealment.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Performance bias.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding of participants and personnel</td>
<td>Describe all measures used, if any, to blind study participants and personnel from knowledge of which intervention a participant received. Provide any information relating to whether the intended blinding was effective.</td>
<td>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study.</td>
</tr>
<tr>
<td>Detection bias.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding of outcome assessment</td>
<td>Describe all measures used, if any, to blind outcome assessors from knowledge of which intervention a participant received. Provide any information relating to whether the intended blinding was effective.</td>
<td>Detection bias due to knowledge of the allocated interventions by outcome assessors.</td>
</tr>
<tr>
<td>Attrition bias.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incomplete outcome data</td>
<td>Describe the completeness of outcome data for each main outcome, including attrition and exclusions from the analysis. State whether attrition and exclusions were reported, the numbers in each intervention group (compared with total randomized participants), reasons for attrition/exclusions where reported, and any re-inclusions in analyses performed by the review authors.</td>
<td>Attrition bias due to amount, nature or handling of incomplete outcome data.</td>
</tr>
<tr>
<td>Reporting bias.</td>
<td>State how the possibility of selective outcome reporting was examined by the review authors, and what was found.</td>
<td>Reporting bias due to selective outcome reporting.</td>
</tr>
<tr>
<td>Selective reporting.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other bias.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other sources of bias.</td>
<td>State any important concerns about bias not addressed in the other domains in the tool. If particular questions/entries were pre-specified in the review’s protocol, responses should be provided for each question/entry.</td>
<td>Bias due to problems not covered elsewhere in the table.</td>
</tr>
</tbody>
</table>

Table 2. A summary of GRADE’s approach to rate the overall quality of evidence.

<table>
<thead>
<tr>
<th>Article</th>
<th>Risk of Bias</th>
<th>Inconsistency</th>
<th>Indirectness</th>
<th>Imprecision</th>
<th>Publication Bias</th>
<th>Overall Quality of Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Megorray et al., 2011 [21]</td>
<td>Not serious</td>
<td>Not serious</td>
<td>Not serious</td>
<td>Not serious</td>
<td>None</td>
<td>High</td>
</tr>
<tr>
<td>Arantes et al., 2009 [22]</td>
<td>Not serious</td>
<td>Not serious</td>
<td>Not serious</td>
<td>Not serious</td>
<td>None</td>
<td>High</td>
</tr>
<tr>
<td>Hussain et al., 2011 [23]</td>
<td>Very serious</td>
<td>Not serious</td>
<td>Not serious</td>
<td>Not serious</td>
<td>None</td>
<td>Low</td>
</tr>
<tr>
<td>Yamasaki et al., 1984 [24]</td>
<td>Very serious</td>
<td>Not serious</td>
<td>Not serious</td>
<td>Not serious</td>
<td>None</td>
<td>Low</td>
</tr>
<tr>
<td>Patil et al., 2005 [25]</td>
<td>Very serious</td>
<td>Not serious</td>
<td>Not serious</td>
<td>Not serious</td>
<td>None</td>
<td>Low</td>
</tr>
<tr>
<td>Sari et al., 2004 [26]</td>
<td>Very serious</td>
<td>Not serious</td>
<td>Not serious</td>
<td>Not serious</td>
<td>None</td>
<td>Low</td>
</tr>
<tr>
<td>Shetty et al., 2013 [27]</td>
<td>Very serious</td>
<td>Not serious</td>
<td>Not serious</td>
<td>Not serious</td>
<td>None</td>
<td>Low</td>
</tr>
<tr>
<td>Karadeniz et al., 2011 [28]</td>
<td>Very serious</td>
<td>Not serious</td>
<td>Not serious</td>
<td>Not serious</td>
<td>None</td>
<td>Low</td>
</tr>
</tbody>
</table>
Effect of Drugs on Orthodontic Tooth Movement

Fig. (1). A flow chart describing the search methodology and numbers of articles included/excluded at each stage.

Fig. (2). Quality assessment of the studies included in the systematic review using “Cochrane risk of bias” tool.
3.3. Results of Individual Studies

3.3.1. Relaxin

The first clinical trial is a randomized double-blinded study in which 39 adults who required a minor maxillary alignment received a series of 4 maxillary aligners, each subject received a weekly 0.2ml injection of Relaxin or placebo over 8 weeks period to the target teeth. Tooth movement was calculated weekly on a PVS impression that was scanned and digitalized. After completing 8 weeks of orthodontic treatment, there was no statistical significance between both the groups. Similarly, there was no statistically significant difference with regard to the relapse of orthodontic treatment over 4 weeks post-treatment between the Relaxin and placebo groups [21].

3.3.2. Tenoxicam

Another double-blinded RCT investigated the effect of Tenoxicam in controlling pain and its influence on orthodontic movement of the upper canine in 36 patients who had an orthodontic indication for bilateral retraction of the upper canine teeth. Group A patients received one tablet of 20 mg of Tenoxicam 45 minutes before the orthodontic activation process and one tablet of placebo after activation. Group B patients received the opposite treatment, and Group C received one tablet of placebo 45 minutes before the procedure and one tablet of placebo just afterward. Subsequently, after 30 days interval, there was no statistically significant difference in orthodontic tooth movement between the 3 groups, but patients in groups A and B had lower pain intensity than those in group C. Thus, Tenoxicam used only once daily was shown to be effective for pain control, without having a significant influence on orthodontic tooth movement [22].

3.3.3. Calcitriol (Vitamin D3)

In this RCT, 15 patients who required bilateral maxillary canine retraction were randomly allocated into three groups, each treated with a specific dose of vitamin D3 (15 μg, 25 μg and 40 μg, respectively). In the experimental site, a specific dose of Calcitriol was injected locally in the distal side of the canine, while the control side received 0.2 ml of vehicle. As a result, the experimental site in groups 1 and 3 showed about 10% higher clinical net rate of canine movement compared to the control site. In group 2, the experimental site demonstrated 51.0% increase in OTM movement compared to the control site. This suggests that locally injected calcitriol, in a specific dose is cost-effective in increasing orthodontic tooth movement in humans without any side effect [23].

3.3.4. Prostaglandin E1

Two studies have investigated the effect of PGE1 on orthodontic tooth movement. In the first one, the authors divided patients who required orthodontic treatment with first premolars extraction into 3 phases in which the injection of PGE1 (10 μg) was given to the experimental side (a premolar in phase 1 and a canine in phase 2 and 3) and a vehicle to the control side (a premolar in phase 1 and a canine in phase 2 and 3). The speed of tooth movement in the experimental side of all cases exceeded that of the control side. In most of the cases, the rate of tooth movement on the experimental side was doubled without side effects [24].

In the second study, 15 patients who required extraction of first premolars for the correction of their malocclusions were injected a 1g of PGE1 in a solution in the right upper quadrant, and a vehicle in the left side. Injections were given on the 1st day, 6th day and 17th day of the start of canine retraction. The mean values of tooth movement in a 2 months period for the right and left canines were 3.5 mm and 2 mm respectively, with a corresponding ratio of 1.7:1 respectively. These results show a significant increase in tooth movement upon PGE1 injection [25].

3.3.5. Acetylsalicylic Acid vs Rofecoxib

This study compared the effect of acetylsalicylic acid and Rofecoxib on PGE2 content in the gingival crevicular fluid in 36 patients with class2 division1 malocclusion receiving orthodontic treatment with maxillary first premolars extraction. 36 patients were divided randomly into three groups. The first group received a 500 mg of acetylsalicylic acid 3 times daily, the second group received 25mg of Rofecoxib on the same day of activation and 12.5 mg on the next day, the third group was the control group and was administered no analgesics. In all groups, the levels of PGE2 increased at 24 and 48 hours and decreased by 168 hours. When comparing the two drugs, it was found that the inhibition effect of acetylsalicylic acid on PGE2 was greater than Rofecoxib, which emphasizes that Rofecoxib is suitable to use as an analgesic to control pain without affecting the outcome of orthodontic treatment [26].

3.3.6. Ibuprofen vs Acetaminophen

This study assessed the effect of Ibuprofen and Acetaminophen on PGE2 levels in 42 patients who received fixed orthodontic treatment in whom maxillary 1st premolars were planned for extraction. Subjects were divided into 3 groups, the first group received 400 mg of ibuprofen 3 times per day for 2 days, the second group was administered acetaminophen 500 mg three times a day for 2 days, and the third group was the control group and received no analgesic. The levels of PGE2 obtained at 24 and 48 hours from the first group which received Ibuprofen was statistically significant when compared to the other groups, unlike Acetaminophen which had no effect on PGE2 synthesis when compared to the control group [27].

3.3.7. Fluoride

This study evaluated the effect of Fluoride concentration in drinking water in 48 patients who required extraction of 96 upper first premolars using both light (25 g) and heavy forces (225 g) delivered buccally to the upper first premolars. Patients were selected from two different cities in Turkey with low and high fluoride concentrations of 0.05 and 2 ppm, respectively. The combination of the level of force and fluoride concentration resulted in a comparison between four groups as follows:

(1) Group 1 high Fluoride-heavy force (HH).
(2) Group 2 low Fluoride-heavy force (LH).
(3) Group 3 high Fluoride-light force (HL).
(4) Group 4 low Fluoride-light force (LL).

2D and 3D evaluation method showed that the greatest tooth movement was in group 1 (HH) followed by group 3 (HL), group 2 (LH) and lastly group 4 (LL) as the average rate of tooth movement was found to be greater in the heavy force and high Fluoride intake group (Group 1) which suggests that both heavy force and high Fluoride intake can accelerate tooth movement [28] (Table 3).

4. DISCUSSION

4.1. Summary of Evidence

This is the first systematic review to be carried out in humans trying to address a very important clinical question i.e. the effect of commonly used medications on orthodontic tooth movement. A systematic review was conducted in 2009 by Bartzela et al., about the effect of medication on orthodontic tooth movement, but considered only a few human studies and most of the studies included were experimental studies on animals [29]. Another systematic review was carried out in 2018 by Makrygiannakis et al., which investigated the effect of common prescription medications on the rate of orthodontic tooth movement included only animal studies [30].

In our systematic review effect of different drugs on orthodontic tooth movement in Humans was investigated, including the dose of each drug used, a method of administration, magnitude of force delivered and methods of evaluating tooth movement. Two clinical trials investigated the effect of PGE1 injections on orthodontic tooth movement which showed a significant acceleration of tooth movement in the injected side compared to the control side even in a very small dosage, whereby in some cases the ratio of tooth movement in the experimental to the control side was almost double. This acceleration in tooth movement is related to the evidence that PGE1 stimulates bone resorption [31].

It was found that the use of tenoxicam (20 mg once daily) to relieve pain during canine retraction, was effective in controlling pain without interfering with orthodontic tooth movement. Other commonly used analgesics such as Paracetamol and Rofecoxib were similar to the control group and had no effect on the level of PGE2, unlike ibuprofen and acetylsalicylic acid which both reduced PGE2 levels significantly in GCF. This is due to the fact that both ibuprofen and acetylsalicylic acid inhibit Cyclooxygenase (COX) enzyme which is responsible for prostaglandins synthesis [33]. These findings suggest that acetylsalicylic acid and ibuprofen as commonly used medications should be avoided or used with caution during orthodontic treatment, while paracetamol and Rofecoxib were the best in controlling pain without interfering with or having any detriment on orthodontic tooth movement.

### Table 3. Summarized published data of the studies included in the systematic review.

<table>
<thead>
<tr>
<th>Article</th>
<th>Material: Size, Gender, Age (Years), Dropout</th>
<th>Drug Used</th>
<th>Dose and Method of Administration</th>
<th>Methods of Force Application</th>
<th>Method of Measurement of GCF/Tooth Movement</th>
<th>Observation Time/Follow-up Time</th>
<th>Impact of Medication on Tooth Movement</th>
<th>Outcome/Author’s Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sari et al., 2004 [26]</td>
<td>• N=36 patients (18 males/18 females) • Mean age: 17.6 • No Drop out</td>
<td>Acetylsalicylic acid vs rofecoxib</td>
<td>• Group 1 received acetylsalicylic acid, 500 mg 3 times daily for 2 days (activation) • Group 2 received rofecoxib 25 mg on the day of activation and 12.5 mg on the next day • Group 3 (control)</td>
<td>72 maxillary canine teeth were distalized with 120g of force delivered by NiTi closed-coil springs</td>
<td>GCF was obtained at baseline and after the activation of closed-coil springs at (1, 2, and 7 days) using 4 filter papers</td>
<td>• Observation time was 7 days • Follow up was not clear</td>
<td>A statistically significant decrease in PGE2 levels in acetylsalicylic acid group at 24 hours unlike rofecoxib which was similar to control group</td>
<td>Rofecoxib can be used during orthodontic treatment without altering tooth movement</td>
</tr>
<tr>
<td>Shetty et al., 2013 [27]</td>
<td>• N=42 patients • Mean age: 18 • No drop out</td>
<td>Ibuprofen and acetaminophen</td>
<td>• Group 1 received 400 mg of ibuprofen 3 times per day for 2 days • Group 2 received 500 mg acetaminophen three times a day for 2 days • Group 3 (control)</td>
<td>The maxillary canines were distalized with 150g of force delivered by NiTi coil springs</td>
<td>GCF sampling was done at baseline and after the activation of the springs at 24, 48 and 168h using micropipette</td>
<td>• 7 days Observation time • Follow up was not clear</td>
<td>The PGE2 levels in the 1st group at 24 and 48 h were significantly less when compared to the acetaminophen and control groups</td>
<td>Ibuprofen inhibits PGE2 synthesis more than acetaminophen</td>
</tr>
<tr>
<td>Article</td>
<td>Material: Size, Gender, Age, Dropout</td>
<td>Drug Used</td>
<td>Dose and Method of Administration</td>
<td>Methods of Force Application</td>
<td>Method of Measurement of GCF/Tooth Movement</td>
<td>Observation Time/Follow-up Time</td>
<td>Impact of Medication on Tooth Movement</td>
<td>Outcome/Author’s Conclusion</td>
</tr>
<tr>
<td>---------</td>
<td>--------------------------------------</td>
<td>------------</td>
<td>----------------------------------</td>
<td>-----------------------------</td>
<td>---------------------------------</td>
<td>-------------------------------</td>
<td>------------------------------------------</td>
<td>------------------------------</td>
</tr>
<tr>
<td>Karadeniz et al., 2011 [28]</td>
<td>N=48 patients (23 males, 25 females)</td>
<td>Fluoride</td>
<td>Group 1 high fluoride-heavy force, Group 2 low fluoride-heavy force, Group 3 high fluoride-light force, Group 4 low fluoride-light force</td>
<td>The patients’ maxillary first premolars were exposed to either heavy (225g) or light (25g) forces were applied using Beta-titanium cantilever springs</td>
<td>2D and 3D evaluation of scanned casts taken before and 4 weeks after activation were superimposed to measure the amount of movement at the buccal and lingual cusps</td>
<td>• 4 weeks treatment period</td>
<td>• Fluoride and heavy forces both increase tooth movement.</td>
<td>• Two- and three-dimensional methods were accurate for the assessment of tooth movement after four weeks of buccal tipping force application when the palatal rugae were used for superimposition</td>
</tr>
<tr>
<td>Yamasaki et al., 1984 [24] (1st phase)</td>
<td>N=9 cases (1 male, 8 females)</td>
<td>Prostaglandin E1</td>
<td>10 µg PGE1 was injected in the submucosal area of the buccal side of the maxillary first premolar in the experimental side</td>
<td>Two double springs were adjusted to the right and left maxillary first premolars with 100 g of force in the buccal direction</td>
<td>Tooth movement was recorded by measuring the distances of the first premolars from the lingual arches</td>
<td>• Treatment time was 35 days</td>
<td>• Prostaglandin to control group ratio was 2.14:1</td>
<td>• Movement of the experimental side was almost doubled with a ratio of 2.14:1 ratio</td>
</tr>
<tr>
<td>Yamasaki et al., 1984 [24] (2nd phase)</td>
<td>N=8 cases (2 males, 6 females)</td>
<td>Prostaglandin E1</td>
<td>10 µg PGE1 was injected in the submucosal area of the distal side of the canine in the experimental side over 2 weeks</td>
<td>Maxillary and Mandibular canines of both sides were distalized with sectional contraction loops archwire using 150g of force</td>
<td>Distal canine movement was considered as the decrease of the distance between the canine and the anchor molars</td>
<td>• 3 weeks treatment time</td>
<td>The treated side showed greater velocity of tooth movement than the untreated side.</td>
<td>• In some cases, tooth movement in the experimental side was doubled</td>
</tr>
<tr>
<td>Yamasaki et al., 1984 [24] (3rd phase)</td>
<td>N=8 cases (2 males, 6 females)</td>
<td>Prostaglandin E1</td>
<td>10 µg PGE1 was injected in the submucosal area of the distal side of the canine in the experimental side over 10 days</td>
<td>The maxillary canines were distalized with compressed open-coil springs or ringlets using 150g force</td>
<td>Distal canine movement was considered as the decrease of the distance between the canine and the anchor molars</td>
<td>• 10 days treatment period</td>
<td>• Prostaglandin to control group ratio was 1.61:1</td>
<td>Tooth movement of the experimental side was more rapid compared to control side without any side effects</td>
</tr>
</tbody>
</table>
Effect of Drugs on Orthodontic Tooth Movement

<table>
<thead>
<tr>
<th>Article</th>
<th>Material: Size, Gender, Age (Years), Dropout</th>
<th>Drug Used</th>
<th>Dose and Method of Administration</th>
<th>Methods of Force Application</th>
<th>Method of Measurement of GCF/Tooth Movement</th>
<th>Observation Time/Follow-up Time</th>
<th>Impact of Medication on Tooth Movement</th>
<th>Outcome/Author’s Conclusion</th>
</tr>
</thead>
</table>
| Hussain et al., 2011 [23] | • N=15 patients | Calciotrol | • 15μg of calcitriol was injected in the distal side of the maxillary canine in the experimental side and 0.2 ml of vehicle in the control side | The right and left maxillary canines retraction was carried out in the 2nd phase using SS base archwire with a distalizing force of 150g | Tooth movement was measured using digital vernier as the distance between the maxillary canine and 2nd premolar before and after treatment. | • 3 weeks treatment | 25 μg of calcitriol produces the greatest tooth movement when compared to control and other groups: 1.57±0.84 mm | • Calciotriol can reduce treatment time up to 12 weeks without any side effect | \*
| Arantes et al., 2009 [22] | • N=36 patients | Tenoxicam | • Group A received 20mg tablet before activation and placebo after | Retraction of the maxillary canines was carried out using NiTi springs | Tooth movement was determined by measuring the distance between the canine and second premolar teeth with a caliper | • 30 days treatment period | OTM was statistically similar between the tenoxicam & placebo groups | Tenoxicam resulted in reduction in pain intensity without alteration in tooth movement |
| Mcgorry et al., 2011 [21] | • N=39 patients (11 males, 28 females) | Relaxin | • 0.2ml of relaxin was injected to the target teeth weekly for 8 weeks | A series of 4 maxillary aligners each of them was dispensed at week 0, 2, 4 and 6 to produce 2mm for the selected maxillary right and left canines | Weekly PVS impressions were scanned and superimposed according to reference points | • 8 weeks treatment time | Average tooth movement over the 8 weeks period was 0.83 mm for the Relaxin group and 0.83mm for the placebo group | • No difference in follow up period |
With regards to other medications such as Relaxin it was found that injections of 0.2 ml of Relaxin weekly over 8 weeks had no effect on tooth movement and was similar to the control group receiving placebo. This may be due to the small dosage used in this experiment as suggested by the authors.

Fluoride concentration may have an impact on orthodontic tooth movement as it was found that high fluoride intake patients had a higher rate of tooth movement than low fluoride patients under both heavy and light force application. Under heavy force, this rate was 22 percent higher while under light force it was 8 percent higher.

When comparing the three different doses of calcitriol, it was found that 25 micrograms were the most effective dose to accelerate tooth movement by 51% when compared to the experimental group. This may suggest that locally injected calcitriol in a specific dose is cost-effective measure for usage clinically to accelerate orthodontic tooth movement in humans. This acceleration in tooth movement can be attributed to the ability of calcitriol to stimulate bone resorption by inducing osteoclasts differentiation from their precursors [34].

A study carried out by Rajasekaran and Nayak comparing the effect of 100 microgram injections of PGE1 over 2 weeks period to cortectomy in 32 canines retraction and space closure patients suggest that cortectomy (0.40 mm/week space closure) is more effective than prostaglandin injection (0.36 mm/week) in accelerating tooth movement, with no statistically significant differences between the two groups regarding the crestal bone height and root length changes [35]. However, as it can be seen above the amount of differences in tooth movement between the two groups (0.04 mm/week) does not seem to be clinically significant.

Older adults are at high risk of developing chronic conditions and disabilities such as diabetes, arthritis and cardiovascular diseases. Some animal studies suggest that regularly consumed drugs by the aged population can have a negative impact on orthodontic tooth movement such as metformin and beta blockers [36, 37]. As more adult patients are now seeking orthodontic treatment [38]. It’s important to understand the mode of action of these drugs and their impact on the whole body including the bone, teeth and their supporting tissues. This will help the orthodontist to form an optimal treatment plan, including the intervals between the regular appointments to adjust the appliances. If a patient is taking a medication for chronic systemic condition which was shown to speed orthodontic tooth movement it may be prudent to shorten the intervals between the appointments to reduce the overall treatment time. If, on the other hand, the medication taken was shown to slow orthodontic tooth movement, then longer interval periods between the appointments will be appropriate to save the clinicians and patient’s time without an impact on the overall duration of orthodontic treatment. Furthermore, drugs can be used during orthodontic treatment as a cost-effective measure to speed orthodontic tooth movement if proven to do so, especially those with no side-effects.

Most of the included studies in the current review failed to state the method of blinding and allocation concealment and thus they were of low quality. This, in addition to the heterogeneities between the studies including the use of different drugs and methods to measure tooth movement, made it not possible to combine their findings using a meta-analysis approach which represents the main shortcoming of this systematic review.

These results emphasize the need for further research including well designed randomized clinical trials to investigate the impact of commonly prescribed drugs during orthodontic treatment on orthodontic tooth movement and

<table>
<thead>
<tr>
<th>Article</th>
<th>Material: Size, Gender, Age (Years), Dropout</th>
<th>Drug Used</th>
<th>Dose and Method of Administration</th>
<th>Methods of Force Application</th>
<th>Method of Measurement of GCF/Tooth Movement</th>
<th>Observation Time/Follow-up Time</th>
<th>Impact of Medication on Tooth Movement</th>
<th>Outcome/Author’s Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patil et al., 2005 [25]</td>
<td>N=15 patients (5 males,10 females) • Mean age: 17.78 • 1 case dropped out</td>
<td>Prostaglandin E1</td>
<td>• 1g of PGE1 was injected in the distal side of the right maxillary canine • 1g of Lignocaine as a vehicle was injected in the distal side of the left maxillary canine as a control • These injections were repeated three times for every subject at 3 visits (the 1st day, 6th day and 17th day of the start of canine retraction)</td>
<td>Canine retraction was performed using NiTi retraction coil springs with 150g of light continuous force</td>
<td>Occlusalgram of pre and post retraction models were superimposed using specific landmarks, distance traveled by tip of canine was measured with a digital caliper</td>
<td>• 60 days treatment duration • Follow up was not clear</td>
<td>• Mean value of tooth movement in the PGE1 experimental side was 3.5 mm • Mean value of tooth movement in the control side was 2mm</td>
<td>Significant increase of tooth movement of the experimental canine compared to the control canine with a ratio of 1.7:1 and no side effects</td>
</tr>
</tbody>
</table>

(Table 3) contd...
other non-invasive medications to increase the rate of orthodontic tooth movement.

CONCLUSION

- This review emphasizes the absence of high-quality evidence of the impact of drugs on orthodontic tooth movement. Bearing in mind the low quality of the evidence of the included studies, it was found that acetylsalicylic acid and ibuprofen reduced orthodontic tooth movement whereas paracetamol, Rofecoxib and tenoxican had no impact on orthodontic tooth movement.

- It is the orthodontist’s role to carefully record the medical and drug history of each patient in order to avoid further lengthening in the treatment time as well as to provide a successful treatment plan.

- To base our practice on scientific evidence, better-controlled RCTs are needed to investigate the impact of common medications on orthodontic tooth movement.

CONSENT FOR PUBLICATION

Not applicable.

FUNDING

None.

CONFLICT OF INTEREST

The authors declare no conflict of interest, financial or otherwise.

ACKNOWLEDGEMENTS

Declared none.

REFERENCES


[http://dx.doi.org/10.1016/j.ajodo.2003.04.006] [PMID: 15014407]

[http://dx.doi.org/10.1186/2196-1042-14-6] [PMID: 24325834]

[PMID: 22372624]

[http://dx.doi.org/10.1016/j.ajodo.2008.08.016] [PMID: 19121496]


[http://dx.doi.org/10.1177/00220345740530032601]


[http://dx.doi.org/10.1177/00220345800590101301] [PMID: 6932420]


[http://dx.doi.org/10.1016/j.ajodo.2003.04.006] [PMID: 15014407]


[http://dx.doi.org/10.1016/0889-5406(88)90052-2] [PMID: 3177281]

[http://dx.doi.org/10.4103/0970-9290.152170] [PMID: 25728102]

[http://dx.doi.org/10.1007/s10735-016-9707-y] [PMID: 27981392]

[http://dx.doi.org/10.1016/j.archoralbio.2014.06.006] [PMID: 25033380]

[PMID: 19506747]

© 2019 Khalaf and Mando.
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: (https://creativecommons.org/licenses/by/4.0/legalcode). This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.